Document is current
Any future updates will be listed below
-
Authors
Lutz, Johannes https://orcid.org/0000-0001-7452-0023
Feist, Randi K. https://orcid.org/0000-0001-5201-8366
Sonntag, Tim https://orcid.org/0000-0001-8487-6963
Peguero-Sánchez, Esteban https://orcid.org/0000-0002-8317-5572
Wolter, Katharina
Bick, Ronja https://orcid.org/0000-0001-7618-887X
Bauer, Jens https://orcid.org/0000-0003-3731-2385
Walz, Juliane S. https://orcid.org/0000-0001-6404-7391
Heidenreich, Regina https://orcid.org/0000-0002-8607-9412
-
Funding
Funding for this research was provided by:
CureVac SE
- License Information
-
More Information
Article History
Received: 2 July 2025
Accepted: 11 September 2025
First Online: 6 October 2025
Declarations
:
: J.L, R.K.F, T.S, E.P-S, K.W, R.B, and R.H are employees of CureVac and may hold company shares/stock options. J.B is shareholder of CureVac. J.S.W is co-founder of ViferaXS GmbH.
: The animal experimental protocols were approved by the ethics committee of the Tübingen Regional Council.
: Not applicable.
